miRNA-155在急性髓性白血病不同阶段中的表达及临床意义

摘要

目的:分析血浆miRNA-155在急性髓性白血病不同阶段中的表达.方法:选取急性髓性白血病21例和健康对照组20例,抽取空腹静脉血,离心后取血浆,直接扩增目的miRNA,并反转录为cDNA,qRT-PCR方法检测血浆miRNA-155的表达.结果:急性髓性白血病初诊组血浆miRNA-155的表达显著高于正常对照组和缓解组,初诊组与未缓解组之间无统计学差异,缓解组与未缓解组之间有统计学差异.结论:血浆miRNA-155在急性髓性白血病不同阶段中的表达不同,有一定的诊断、治疗、预后评估意义.%Objective:To investigate the level of miRNA-155 in plasma of acute myeloid leukemia (AML)pa-tients at different disease phase.Methods:21 AML patients and 20 healthy controls were enrolled in this study and their plasma samples were acquired by density gradient centrifugation.miRNA in plasma was firstly reversed to cDNA and then real-time quantitative PCR (qPCR)was used to detect the expression level of miRNA-155.Results:The expression of miR-155 was significantly higher in de novo AML group than that in remmison group and healthy con-trol group.There was no significant difference between de novo AML group and non-remission group,while signifi-cant difference was observed between remission group and non-remission group.Conclusion:miRNA-155 in plas-ma from AML patients at different disease phase is at different expression level,and is useful for diagnosis,treatment and prognosis evaluation.